Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !
Guangzhou Baiyunshan Pharmaceutical Holdings Balance Sheet Health
Finanzielle Gesundheit Kriterienprüfungen 5/6
Guangzhou Baiyunshan Pharmaceutical Holdings hat ein Gesamteigenkapital von CN¥38.7B und eine Gesamtverschuldung von CN¥13.2B, wodurch sich der Verschuldungsgrad auf 34.2% beläuft. Die Gesamtaktiva und Gesamtpassiva betragen CN¥78.7B bzw. CN¥40.0B. Guangzhou Baiyunshan Pharmaceutical Holdings Das EBIT des Unternehmens beträgt CN¥4.7B, so dass der Zinsdeckungsgrad -15 beträgt. Das Unternehmen verfügt über Barmittel und kurzfristige Anlagen in Höhe von CN¥19.8B.
Wichtige Informationen
34.2%
Verhältnis von Schulden zu Eigenkapital
CN¥13.24b
Verschuldung
| Zinsdeckungsgrad | -15x |
| Bargeld | CN¥19.76b |
| Eigenkapital | CN¥38.71b |
| Gesamtverbindlichkeiten | CN¥39.99b |
| Gesamtvermögen | CN¥78.70b |
Jüngste Berichte zur Finanzlage
Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13
Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Recent updates
The CEO Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Might See A Pay Rise On The Horizon
May 23Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
May 13Do Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Earnings Warrant Your Attention?
Mar 08Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 33% Above Its Share Price
Feb 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has More To Do To Multiply In Value Going Forward
Feb 10Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Jan 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Popularity With Investors Is Under Threat From Overpricing
Jan 09With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Nov 28A Look At The Intrinsic Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 15We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Oct 19Returns On Capital At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have Hit The Brakes
Oct 03Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Worth HK$21.9 Based On Its Intrinsic Value?
Aug 15Should You Be Adding Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) To Your Watchlist Today?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings' (HKG:874) Returns Have Hit A Wall
Jul 02Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jun 01Here's Why Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Caught The Eye Of Investors
May 01The Returns At Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Aren't Growing
Mar 28Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Feb 23With EPS Growth And More, Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Makes An Interesting Case
Jan 23Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has Some Way To Go To Become A Multi-Bagger
Dec 24Estimating The Fair Value Of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874)
Nov 24Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Using Too Much Debt?
Nov 11Does Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Have A Healthy Balance Sheet?
Aug 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Paying Out A Larger Dividend Than Last Year
May 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Intrinsic Value Is Potentially 83% Above Its Share Price
Apr 29Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Could Easily Take On More Debt
Apr 10We Think Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Can Manage Its Debt With Ease
Jan 09Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Rock Solid Balance Sheet
Oct 11Is Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) A Risky Investment?
Jul 12Why We Think Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) CEO Compensation Is Not Excessive At All
May 26How Does Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stand Up To These Simple Dividend Safety Checks?
Apr 30Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Shares Could Be 21% Above Their Intrinsic Value Estimate
Apr 08These 4 Measures Indicate That Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Is Using Debt Reasonably Well
Mar 25Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's (HKG:874) Stock Has Been Sliding But Fundamentals Look Strong: Is The Market Wrong?
Mar 02Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Shareholders Have Enjoyed A 24% Share Price Gain
Feb 11
Is Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) A Smart Pick For Income Investors?
Jan 26Could The Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Ownership Structure Tell Us Something Useful?
Jan 06Guangzhou Baiyunshan Pharmaceutical Holdings (HKG:874) Has A Pretty Healthy Balance Sheet
Dec 23Here's Why We Don't Think Guangzhou Baiyunshan Pharmaceutical Holdings's (HKG:874) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 09Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (HKG:874) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?
Nov 26Analyse der Finanzlage
Kurzfristige Verbindlichkeiten: 874Die kurzfristigen Aktiva des Unternehmens (CN¥56.0B) übersteigen seine kurzfristigen Passiva (CN¥34.1B).
Langfristige Verbindlichkeiten: 874Die kurzfristigen Vermögenswerte des Unternehmens (CN¥56.0B) übersteigen seine langfristigen Verbindlichkeiten (CN¥5.9B).
Geschichte und Analyse des Verhältnisses von Schulden zu Eigenkapital
Verschuldungsgrad: 874 über mehr Barmittel verfügt als seine Gesamtverschuldung.
Schulden abbauen: 874Das Verhältnis von Schulden zu Eigenkapital ist in den letzten 5 Jahren von 32% auf 34.2% gestiegen.
Schuldendeckung: 874Die Schulden des Unternehmens sind gut durch den operativen Cashflow gedeckt (28.7%).
Zinsdeckung: 874 mehr Zinsen einnimmt als er zahlt, so dass die Deckung der Zinszahlungen kein Problem darstellt.